License and Collaboration Agreements - Additional Information (Detail)			1 Months Ended		3 Months Ended
	May 31, 2020 USD ($)	Nov. 30, 2018 USD ($)	Nov. 30, 2021 USD ($)	Nov. 30, 2018 USD ($)	Mar. 31, 2022 USD ($) ProductCandidate	Mar. 31, 2021 USD ($)	Dec. 31, 2021 USD ($)	Dec. 31, 2020 USD ($)	Jul. 31, 2020 USD ($)
License Revenue [Line Items]
Milestone payment upon commencement of clinical trials in humans					$ 537,800,000
Milestone payment upon submission of regulatory approval filings					21,000,000.0
Milestone payment upon approval of commercial products by regulatory agencies					141,000,000.0
Milestone payment upon achievement of specified sales targets for licensed products					877,000,000.0
Deferred revenue, current and non-current					3,333,000	$ 4,124,000	$ 3,333,000	$ 4,232,000
Provision for credit losses					0	565,000
Accounts receivable, current					27,022,000		32,439,000
Accounts receivable, net					2,084,000		2,262,000
Abeona Therapeutics Incorporation | Contract Termination
License Revenue [Line Items]
Up-front and annual fees		$ 20,000,000.0		$ 20,000,000.0
Abb Vie Collaboration And License Agreement
License Revenue [Line Items]
Up-front fee paid			$ 370,000,000.0
Milestone fee payments upon achievement of various development and commercialization			1,380,000,000
Transaction price of license					370,000,000.0		370,000,000.0
Change in transaction price					0
Revenue recognized					0
Reimbursement of development costs					2,974,000
Abb Vie Collaboration And License Agreement | Other Current Assets [Member]
License Revenue [Line Items]
Reimbursement of development costs					3,100,000		5,900,000
March 2014 License Agreement [Member] | Novartis Gene Therapies [Member]
License Revenue [Line Items]
Accounts receivable					21,000,000.0		26,600,000
November Two Thousand Eighteen License Agreement | Abeona Therapeutics Incorporation
License Revenue [Line Items]
License fee				$ 8,000,000.0
November Two Thousand Eighteen License Agreement | Abeona Therapeutics Incorporation | Contract Termination
License Revenue [Line Items]
Accounts receivable	$ 28,000,000.0								$ 33,600,000
License agreement termination claims, description	after the termination of the November 2018 License, Abeona filed a claim in arbitration alleging that the Company had breached certain responsibilities to communicate with Abeona regarding the Company’s prosecution of licensed patents under the November 2018 License. The Company disputed Abeona’s claim and filed a counterclaim in arbitration demanding payment of the $28.0 million of unpaid fees from Abeona, plus accrued interest.	As a result of the termination, Abeona was required to pay an additional $20.0 million license fee to the Company within 15 days of the termination date, which otherwise would have been due to the Company in November 2020.
Interest percentage on unpaid balances under license agreement				1.50%
Settlement agreement payable					30,000,000.0
November Two Thousand Twenty One License Agreement | Abeona Therapeutics Incorporation | Contract Termination
License Revenue [Line Items]
Settlement agreement payable					20,000,000.0
November Two Thousand Twenty Two License Agreement | Abeona Therapeutics Incorporation | Contract Termination
License Revenue [Line Items]
Settlement agreement payable					5,000,000.0
November Two Thousand Twenty Four License Agreement | Abeona Therapeutics Incorporation | Contract Termination
License Revenue [Line Items]
Settlement agreement payable					5,000,000.0
Settlement Agreement | Abeona Therapeutics Incorporation
License Revenue [Line Items]
Accounts receivable					8,900,000		8,800,000
Accounts receivable, current					5,000,000.0
Accounts receivable, net					3,900,000
Payments due from related party					5,000,000.0
Allowance for credit losses					3,900,000		3,800,000
Provision for credit losses					0	$ 600,000
Sales Based Milestones | Abb Vie Collaboration And License Agreement
License Revenue [Line Items]
Milestone fee payments upon achievement of various development and commercialization			820,000,000.0
Transaction price of license					820,000,000.0		820,000,000.0
Development Milestone | Abb Vie Collaboration And License Agreement
License Revenue [Line Items]
Milestone fee payments upon achievement of various development and commercialization			$ 562,500,000
Transaction price of license					562,500,000		$ 562,500,000
Maximum [Member]
License Revenue [Line Items]
Aggregate milestone payment for all the targets					$ 1,580,000
N A V Technology Platform [Member]
License Revenue [Line Items]
Number of commercial product candidates | ProductCandidate					1
HCR [Member] | March 2014 License Agreement [Member] | Novartis Gene Therapies [Member]
License Revenue [Line Items]
Accounts receivable, current					$ 14,300,000